Michael SchÃ¶ll

List of Publications by Year
in descending order

134	10,404	44069	37204
papers	citations	48	96
		h-index	g-index

147	147	147	9575
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PET Imaging of Tau Deposition in the Aging Human Brain. Neuron, 2016, 89, 971-982.	8.1	899
2	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain, 2016, 139, 1551-1567.	7.6	833
3	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	10.2	668
4	Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	12.8	596
5	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	8.7	404
6	Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by ^{11}C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining ^{11}C-Pittsburgh Compound B and ^{18}F-FDG. Journal of Nuclear Medicine, 2012, 53, 37-46.	5.0	354
7	Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	7.4	298
8	The continuum of spreading depolarizations in acute cortical lesion development: Examining Leão's legacy. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1571-1594.	4.3	297
9	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	7.7	285
10	Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1595-1625.	4.3	255
11	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain, 2016, 139, 922-936.	7.6	235
12	Microglial activation and tau propagate jointly across Braak stages. Nature Medicine, 2021, 27, 1592-1599.	30.7	235
13	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	12.8	219
14	A walk through tau therapeutic strategies. Acta Neuropathologica Communications, 2019, 7, 22.	5.2	211
15	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	7.9	186
16	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.8	174
17	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	2.2	163
18	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.1	161

#	Article	IF	Citations
19	^{18}F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine, 2017, 9, 1212-1223.	6.9	156
20	^{18}F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in *MAPT* mutation carriers. Brain, 2016, 139, 2372-2379.	7.6	149
21	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. Brain, 2017, 140, 2286-2294.	7.6	149
22	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146
23	Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic *APP* mutation carriers. Neurology, 2012, 79, 229-236.	1.1	138
24	Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain, 2011, 134, 301-317.	7.6	126
25	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathologica Communications, 2019, 7, 5.	5.2	125
26	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Brain, 2021, 144, 325-339.	7.6	124
27	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.1	122
28	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	10.1	121
29	Increased basal ganglia binding of ^{18}F-AV-1451 in patients with progressive supranuclear palsy. Movement Disorders, 2017, 32, 108-114.	3.9	111
30	Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. Scientific Reports, 2015, 5, 16404.	3.3	110
31	In vivo retention of ^{18}F-AV-1451 in corticobasal syndrome. Neurology, 2017, 89, 845-853.	1.1	103
32	Imaging biomarkers in neurodegeneration: current and future practices. Alzheimer's Research and Therapy, 2020, 12, 49.	6.2	96
33	Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. Brain, 2018, 141, 2755-2771.	7.6	89
34	Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. Frontiers in Neuroscience, 2017, 11, 167.	2.8	87
35	Predicting diagnosis and cognition with ^{18}F-AV-1451 tau PET and structural MRI in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 570-580.	0.8	84
36	Comparing ^{18}F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology, 2018, 90, e388-e395.	1.1	83

#	ARTICLE	IF	CITATIONS
37	Prediction of AD dementia by biomarkers following the NIA–AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.8	71
38	Amyloid and tau PET demonstrate region-specific associations in normal older people. NeuroImage, 2017, 150, 191-199.	4.2	67
39	Comparison of Early-Phase ^{11}C-Deuterium-l-Deprenyl and ^{11}C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 1071-1077.	5.0	63
40	Current advances in digital cognitive assessment for preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12217.	2.4	63
41	Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathologica, 2017, 133, 149-151.	7.7	61
42	Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 342-354.	6.4	61
43	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Brain, 2020, 143, 3793-3804.	7.6	60
44	18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. Scientific Reports, 2018, 8, 4717.	3.3	59
45	Update on biomarkers for amyloid pathology in Alzheimer's disease. Biomarkers in Medicine, 2018, 12, 799-812.	1.4	59
46	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. Science Advances, 2019, 5, eaau7220.	10.3	59
47	Fluorodeoxyglucose PET in Neurology and Psychiatry. PET Clinics, 2014, 9, 371-390.	3.0	58
48	Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Molecular and Cellular Neurosciences, 2019, 97, 34-42.	2.2	55
49	Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2120-2126.	6.4	53
50	No association of salivary total tau concentration with Alzheimer's disease. Neurobiology of Aging, 2018, 70, 125-127.	3.1	51
51	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1231-1241.	1.9	51
52	Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. Biological Psychiatry, 2020, 87, 808-818.	1.3	50
53	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology, 2021, 97, .	1.1	50
54	Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiology of Aging, 2011, 32, 1388-1399.	3.1	48

#	ARTICLE	IF	CITATIONS
55	Combination of 18F-FDG PET and Cerebrospinal Fluid Biomarkers as a Better Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment Patients. Journal of Alzheimer's Disease, 2013, 33, 929-939.	2.6	48
56	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid–positive individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 679-689.	2.4	48
57	Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.1	42
58	Relevance of biomarkers across different neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 56.	6.2	42
59	Plasma p–tau231, p–tau181, <scp>PET</scp> Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	5.3	42
60	Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms. JAMA Network Open, 2022, 5, e2213253.	5.9	35
61	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20.	6.2	32
62	Time Course of Glucose Metabolism in Relation to Cognitive Performance and Postmortem Neuropathology in Met146Val PSEN1 Mutation Carriers. Journal of Alzheimer's Disease, 2011, 24, 495-506.	2.6	30
63	Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2212-2224.	6.4	29
64	Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease. Brain, 2021, 144, 2284-2290.	7.6	29
65	Data–driven approaches for tau–PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping, 2019, 40, 638-651.	3.6	27
66	Biomarkers for Microglial Activation in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-5.	2.0	23
67	CSF biomarkers and plasma p–tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's and Dementia, 2022, 18, 2614-2626.	0.8	22
68	Detection of Alzheimer's Disease. Yale Journal of Biology and Medicine, 2018, 91, 291-300.	0.2	21
69	Multimodality Imaging Approach in Alzheimer disease. Part I: Structural MRI, Functional MRI, Diffusion Tensor Imaging and Magnetization Transfer Imaging. Dementia E Neuropsychologia, 2015, 9, 318-329.	0.8	19
70	Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum. Scientific Reports, 2019, 9, 15385.	3.3	19
71	Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. International Journal of Geriatric Psychiatry, 2018, 33, 1305-1311.	2.7	16
72	Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	3.1	15

#	Article	IF	Citations
73	Tau Seeding Mouse Models with Patient Brain-Derived Aggregates. International Journal of Molecular Sciences, 2021, 22, 6132.	4.1	14
74	Deep learning from MRI-derived labels enables automatic brain tissue classification on human brain CT. NeuroImage, 2021, 244, 118606.	4.2	13
75	Cortical Spreading Depression Dynamics Can Be Studied Using Intrinsic Optical Signal Imaging in Gyrencephalic Animal Cortex. , 2013, 118, 93-97.		13
76	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimer's Research and Therapy, 2018, 10, 45.	6.2	11
77	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	3.6	11
78	Lower ^{68}Ga–DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland—A proof–of–concept study. Clinical Endocrinology, 2020, 92, 222-231.	2.4	11
79	Head–to–head comparison of amplified plasmonic exosome Aβ42 platform and single–molecule array immunoassay in a memory clinic cohort. European Journal of Neurology, 2021, 28, 1479-1489.	3.3	11
80	Association of APOE ε4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function. Journal of Alzheimer's Disease, 2022, 85, 1309-1320.	2.6	11
81	Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community–based sample of 70–year–olds. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12295.	2.4	11
82	Linking Amyloid-β and Tau Deposition in Alzheimer Disease. JAMA Neurology, 2017, 74, 766.	9.0	10
83	Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes. Neurology, 2022, 99, .	1.1	10
84	Does early cognitive decline require the presence of both tau and amyloid-β?. Brain, 2020, 143, 10-13.	7.6	9
85	Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2283-2294.	6.4	9
86	Comparison of Two-Dimensional- and Three-Dimensional-Based U-Net Architectures for Brain Tissue Classification in One-Dimensional Brain CT. Frontiers in Computational Neuroscience, 2021, 15, 785244.	2.1	9
87	Pre–and postoperative ^{68}Ga–DOTATOC positron emission tomography for hormone–secreting pituitary neuroendocrine tumours. Clinical Endocrinology, 2021, 94, 956-967.	2.4	7
88	IC-01-05: In vivo braak staging using 18F-AV1451 Tau PET imaging. , 2015, 11, P4-P4.		5
89	Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2223-2232.	4.3	5
90	Imaging tau pathology in Alzheimer's disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies. Molecular Neurodegeneration, 2022, 17, .	10.8	5

#	Article	IF	Citations
91	IC-P-161: Tau PET with [18 F]AV1451 in non-alzheimer's disease neurodegenerative syndromes. , 2015, 11, P107-P109.		4
92	Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET. Dementia E Neuropsychologia, 2015, 9, 330-342.	0.8	4
93	P1â€318: TAUâ€PET Patterns Overlap and Exceed Hypometabolism in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P545.	0.8	2
94	O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545.	0.8	2
95	Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein. Journal of Alzheimer's Disease, 2021, 80, 813-829.	2.6	2
96	IC-02-02: Distinct [18 F]AV1451 retention patterns in clinical variants of Alzheimer's disease. , 2015, 11, P5-P6.		1
97	[P4â€"525]: DATAâ€DRIVEN TAUâ€PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1548.	0.8	1
98	ICâ€Pâ€070: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P64.	0.8	1
99	O5â€01â€01: HEADâ€TOâ€HEAD IN VIVO COMPARISON OF TAU POSITRON EMISSION TOMOGRAPHY LIGANDS 18Fâ€FLORTAUCIPIR AND 18Fâ€RO948. Alzheimer's and Dementia, 2019, 15, .	0.8	1
100	Tau pathology progression across PETâ€based stages of regional amyloid deposition. Alzheimer's and Dementia, 2021, 17, .	0.8	1
101	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
102	IC-P-126: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P86-P86.		0
103	IC-P-157: Associations of [18 F]AV1451 Tau PET with age, ApoE genotype, and cognition in Alzheimer's disease. , 2015, 11, P105-P106.		0
104	IC-P-168: Examining relations of age and beta-amyloid with tau deposition measured using 18F-AV-1451 in cognitively normal older adults. , 2015, 11, P111-P112.		0
105	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
106	F2-03-01: Tau and amyloid neuroimaging of ad phenotypes. , 2015, 11, P167-P167.		0
107	O5-01-04: Cognitive decline in healthy elderly is related to temporal lobe tau but not to cortical β-amyloid: An 18F-AV1451 and 11C-PiB PET study. , 2015, 11, P313-P314.		0
108	P4â€339: Earlyâ€and Lateâ€Onset Alzheimerâ€™S Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]Fâ€AVâ€1451 TAU Positron Emission Tomography. Alzheimer's and Dementia, 2016, 12, P1164.	0.8	0

#	Article	IF	Citations
109	IC-P-193: Examining Amyloid and TAU Inter-Regional PET Association Patterns in Cognitively Normal Older Adults. , 2016, 12, P139-P140.		0
110	O3â€08â€04: Tau Covariance Patterns in Alzheimer's Disease Patients Resemble Intrinsic Connectivity Networks in Young Adults. Alzheimer's and Dementia, 2016, 12, P305.	0.8	0
111	O4-09-01: An Nrem Sleep Signature of Human in Vivo TAU Burden. , 2016, 12, P353-P353.		0
112	ICâ€Pâ€192: TAU Covariance Patterns in ad Patients Resemble Intrinsic Connectivity Networks in Young Adults. Alzheimer's and Dementia, 2016, 12, P138.	0.8	0
113	[ICâ€Pâ€199]: [18]Fâ€AVâ€1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION. Alzheimer's and Dementia, 2017, 13, P146.	0.8	0
114	[O1â€"06â€"06]: SPATIAL CORRESPONDENCE OF ALZHEIMER's DISEASEâ€RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS. Alzheimer's and Dementia, 2017, 13, P203.	0.8	0
115	[P4â€"407]: REGIONAL DIFFERENCES IN THE TRANSIENT EQUILIBRIUM OF [^{18}F]AVâ€1451 AND THEIR IMPACT ON TISSUE UPTAKE RATIOS. Alzheimer's and Dementia, 2017, 13, P1486.	0.8	0
116	[P4â€"502]: THE EARLIEST STAGES OF AMYLOID ACCUMULATION ARE ASSOCIATED WITH INCREASED FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2017, 13, P1531.	0.8	0
117	[ICâ€Pâ€195]: SPATIAL CORRESPONDENCE OF ALZHEIMER's DISEASEâ€RELATED TAU PATHOLOGY AND GREY MATTER ATROPHY DISTRIBUTION WITH INTRINSIC FUNCTIONAL BRAIN NETWORKS. Alzheimer's and Dementia, 2017, 13, P143.	0.8	0
118	ICâ€Pâ€218: ^{18}Fâ€FLORTAUCIPIR (AVâ€1451) RETENTION IN PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2018, 14, P178.	0.8	0
119	P3â€243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1165.	0.8	0
120	O1â€07â€02: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXELâ€BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, .	0.8	0
121	F4â€05â€01: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1224.	0.8	0
122	ICâ€Pâ€071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P65.	0.8	0
123	ICâ€Pâ€072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXELâ€BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P66.	0.8	0
124	CTâ€based brain segmentation and volumetry using deep learning methods. Alzheimer's and Dementia, 2020, 16, e045824.	0.8	0
125	University College London/University of Gothenburg PhD course â€œBiomarkers in neurodegenerative diseasesâ€•2019â€"course organisation. Alzheimer's Research and Therapy, 2020, 12, 18.	6.2	0
126	PET Biomarkers for Tau Pathology. , 2020, , 227-234.		0

#	Article	IF	Citations
127	Impact of reduced injected dose on the quantification of [¹⁸ F]RO948 and [¹⁸ F]Flortaucipir PET for <i>in vivo</i> tau pathology. Alzheimer's and Dementia, 2021, 17, .	0.8	0
128	When is a biomarker an AD biomarker? Face versus construct validity and practical implications for differential application. Alzheimer's and Dementia, 2021, 17, .	0.8	0
129	Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. Alzheimer's and Dementia, 2021, 17, .	0.8	0
130	Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2021, 17, .	0.8	0
131	Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
132	Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. Alzheimer's and Dementia, 2021, 17, .	0.8	0
133	Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community€based population of 70€year€olds. Alzheimer's and Dementia, 2021, 17, .	0.8	0
134	Association of deep€learning€"derived brain computed tomography measures with cognition and blood€based biomarkers of neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, .	0.8	0